Table 1.

Kinetic characteristics of HLA-A*0201/NY-ESO-1157–165–specific TCR variants

SPR TCR–pMHC kineticsbNTAmer dissociation kineticsNTAmer227–228 dissociation kinetics
Soluble TCRsCD8+cCD8cCD8+cCD8c
konkoffkoffkoffkoffkoff
TCR variantsaKD μmol/L1/[(mol/L)× s] (×104)1/s (×10−2)t1/2 s1/s (×10−2)t1/2 s1/s (×10−2)t1/2 s1/s (×10−2)t1/2 s1/s (×10−2)t1/2 s
V49In.a.n.a.n.a.n.a.21.213n.a.n.a.n.a.n.a.n.a.n.a.
Wild-type21.41.123.034.081710.2711.2615.45
G50A4.621.56.9101.4747n.d.n.d.5.2813n.d.n.d.
A97L2.692.36.1111.6044n.d.n.d.4.7015n.d.n.d.
DMβ1.912.44.5150.78902.76253.02233.1522
TMβ0.911.41.3530.282471.03670.87790.9772
TMα0.4012.14.8140.44158n.d.n.d.1.7640n.d.n.d.
QMα0.1410.91.5460.213410.80870.74940.7592
Wtc51m0.0158.50.135330.0515050.144970.154750.14496

Abbreviations: n.a., not applicable; n.d., not done.

  • aWild-type TCR (BC1; AV23.1/BV13.1) was isolated from melanoma patient LAU 155 (16) and a panel of TCR variants of progressive increasing affinities against HLA-A*0201/NY-ESO-1157–165 was established as described in ref. 20.

  • bTCR–pMHC affinity, koff and kon values were previously measured by SPR as reported in ref. 20.

  • cCD8+ T cells, TCR-transduced SUP-T1 cells; CD8 T cells, TCR-transduced Jurkat cells.